EN | RU
EN | RU

Help Support

Back

Clopidogrel reduces major bleeding events in diabetes patients undergoing PCI

Percutaneous Coronary Intervention Percutaneous Coronary Intervention
Percutaneous Coronary Intervention Percutaneous Coronary Intervention

What's new?

In individuals with diabetes undergoing PCI, Clopidogrel monotherapy reduces major bleeding events.

In diabetes patients undergoing percutaneous coronary intervention (PCI) following a very brief dual antiplatelet therapy (DAPT), Clopidogrel monotherapy was associated with an effective reduction in major bleeding events without a rise in cardiovascular events. This study's objective was to assess the safety and effectiveness of Clopidogrel monotherapy during PCI.

A subgroup assessment was done based on diabetes in STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2) Total Cohort (N = 5,997) (STOPDAPT-2, n = 3,009; STOPDAPT-2 ACS [Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2 for Patients With ACS], n = 2,988), that randomly investigated one-month DAPT succeeded by Clopidogrel monotherapy along with twelve-month DAPT with Aspirin and Clopidogrel following cobalt-chromium everolimus-eluting stent implantation.

The composite of TIMI [Thrombolysis In Myocardial Infarction] major or mild bleeding or cardiovascular (myocardial infarction, cardiovascular mortality, definite stent thrombosis, or stroke) endpoints at 1 year was the key endpoint ascertained. Notably, 2,030 people (33.8%) had diabetes in comparison with 3967 without it (66.2%).

Without regard to diabetes, the risk of one-month DAPT relative to twelve-month DAPT was not statistically profound for the key outcome (nondiabetes, 2.46% vs 2.49% [HR: 0.99]; diabetes, 3.58% vs 4.12% [HR: 0.87]) and for the cardiovascular endpoint (nondiabetes, 1.95% vs 1.43% [HR: 1.38]; diabetes, 3.28% vs 3.05% [HR: 1.10]). However, it was lower for the bleeding endpoint (nondiabetes, 0.61% vs 1.21% [HR: 0.51]; diabetes, 0.30% vs 1.50% [HR: 0.20]).

Irrespective of diabetes, Clopidogrel monotherapy following 1-month DAPT in comparison with 12-month DAPT diminished significant bleeding events without elevating cardiovascular events. However, the results must be viewed as hypothesis-generating, particularly in individuals suffering from acute coronary syndrome, owing to inconclusive findings of the STOPDAPT-2 ACS trial's results.

Source:

JACC: Cardiovascular Interventions

Article:

Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention

Authors:

Ko Yamamoto et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: